Biomarkers to Predict Improvement of Left Ventricular Ejection Fraction after Atrial Fibrillation Ablation

Atrial FibrillationHeart Failure

Catheter-based ablation to improve outcomes in patients with atrial fibrillation and heart failure with preserved ejection fraction: Rationale and design of the CABA-HFPEF-DZHK27 trial

Eur J Heart Fail

Parwani AS, Kääb S, Friede T, Tilz RR, Bauersachs J, Frey N, Hindricks G, Lewalter T, Rienstra M, Rillig A, Scherr D, Steven D, Kirchhof P, Pieske B

doi: 10.1002/ejhf.3373

Heart Failure

Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT-CHF (European) study with the ASIAN-HF registry

Eur J Heart Fail

Cao TH, Tay WT, Jones DJL, Cleland JGF, Tromp J, Emmens JE, Teng TK, Chandramouli C, Slingsby OC, Anker SD, Dickstein K, Filippatos G, Lang CC, Metra M, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zannad F, Anand IS, Lam CSP, Voors AA, Ng LL

doi: 10.1002/ejhf.3378

Atrial FibrillationHeart Failure

Effects of Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction: Insights From CABANA

JACC Heart Fail

Martens P, Augusto SN Jr, Erzeel J, Pison L, Mullens W, Tang WHW

doi: 10.1016/j.jchf.2025.01.029

Atrial FibrillationHeart Failure

Catheter Ablation Versus Medical Therapy for Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis

Heart Rhythm

Bulhões E, Antunes VLJ, Mazetto R, Defante MLR, Garcia AC, Guida C

doi: 10.1016/j.hrthm.2024.04.058

Heart Failure

The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high-, middle- and low-income countries - A Global Congestive Heart Failure (G-CHF) study

Eur J Heart Fail

Leong DP, Joseph PG, Dokainish H, Störk S, McMurray JVV, Mielniczuk LM, Sharma SK, Orlandini A, Karaye KM, Bayes-Genis A, McCready T, Grinvalds A, Balasubramanian K, Branch KR, Kragholm K, Yusuf S, on behalf of the G‐CHF Investigators

doi: 10.1002/ejhf.3550

Atrial FibrillationHeart Failure

Importance of non-cardiovascular comorbidities in atrial fibrillation and heart failure with preserved ejection fraction

ESC Heart Fail

Hamatani Y, Iguchi M, Kato T, Inuzuka Y, Tamaki Y, Ozasa N, Kawaji T, Esato M, Tsuji H, Wada H, Hasegawa K, Abe M, Kimura T, Ono K, Akao M, Fushimi AF Registry and KCHF Registry investigators

doi: 10.1002/ehf2.15093

Heart Failure

Investigation of left ventricular ejection fraction in a Swiss heart failure population: Insights into mortality and sex differences

ESC Heart Fail

Fuentes Artiles R, Meçani R, Muka T, Hunziker L, Capék L

doi: 10.1002/ehf2.15174

Heart, Artery and Coronary DiseasesHeart Failure

Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVER

Eur J Heart Fail

Abdin A, Kondo T, Böhm M, Jhund PS, Claggett BL, Vaduganathan M, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Desai AS, Køber L, Sabatine MS, Petersson M, Bachus E, Solomon SD, McMurray JJV, on behalf of the DAPA‐HF and DELIVER Committees and Investigators

doi: 10.1002/ejhf.3350

Heart Failure

Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial

Eur J Heart Fail

Tromp J, Kosiborod MN, Angermann CE, Collins SP, Teerlink JR, Ponikowski P, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Brueckmann M, Blatchford JP, Steubl D, Voors AA

doi: 10.1002/ejhf.3218

Related content

Catheter-based ablation to improve outcomes in patients with atrial fibrillation and heart failure with preserved ejection fraction: Rationale and design of the CABA-HFPEF-DZHK27 trial

Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT-CHF (European) study with the ASIAN-HF registry

Effects of Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction: Insights From CABANA

Catheter Ablation Versus Medical Therapy for Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis

The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high-, middle- and low-income countries - A Global Congestive Heart Failure (G-CHF) study

Importance of non-cardiovascular comorbidities in atrial fibrillation and heart failure with preserved ejection fraction

Investigation of left ventricular ejection fraction in a Swiss heart failure population: Insights into mortality and sex differences

Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVER

Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial